摘要
目的观察TE(多西紫杉醇、吡柔比星)方案在乳腺癌新辅助化疗中的疗效和毒性反应。方法 2008年3月～2011年12月63例Ⅱ～Ⅲ期乳腺癌患者,采用TE方案,具体为多西紫杉醇75 mg/m2静注,d1,吡柔比星50 mg/m2静注,d1;每3周为1个疗程,共行术前新辅助化疗3个疗程,3个疗程后评估疗效和不良反应。结果总有效率(CR+PR)为84.13%,其中CR 5例(7.94%),PR 48例(76.19%);毒性反应多为胃肠道反应、骨髓抑制、脱发等,经治疗后患者得以耐受,无患者因疾病进展影响手术。结论紫杉醇类药物联合蒽环类药物的化疗方案在乳腺癌新辅助化疗中有较好的效果,毒副作用可耐受,是一种有效的乳腺癌Ⅱ～Ⅲ期新辅助化疗方案。
Objective To observe the therapeutic efficacy and toxicity of TE （Docetaxel, Pirarubicin） plan in neoadjuvant chemotherapy of breast cancer. Methods 63 cases of stage [I and III breast cancer were given TE plan （specifically intravenous injection of 75 mg/m^2 Docetaxel, dl, intravenous injection of 50 mg/m^2 Pirarubicin, dl） and neoadjuvant chemotherapy for 3 courses, 3 weeks for each course. Treatment efficacy and adverse reactions were assessed after 3 weeks. Results The overall response rate （CR＋PR） was 84.13%, among which, 5 cases （7.94%） were CR and 48 cases （76.19%） were PR; toxicity reactions were mainly gastrointestinal tract reaction, bone marrow suppression and alopecia. The toxicity reactions were bearable after treatment and didn＇t affect surgery due to disease progression. Conclusion Chemotherapy plan of Taxol combined with anthracycline has good efficacy in the treatment of breast cancer. And the relevant toxicity can also be tolerated, thus it is an effective neoadjuvant chemotherapy for phase II and III breast cancer.
出处
《中国医药导报》
CAS
2012年第22期80-81,共2页
China Medical Herald
